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Abstract

Patient navigation has been proposed to combat cancer disparities in vulnerable populations. Vulnerable populations
often have poorer cancer outcomes and lower levels of screening, adherence, and treatment. Navigation has been studied
in various cancers, but few studies have assessed navigation in lung cancer. Additionally, there is a lack of consistency in
metrics to assess the quality of navigation programs. The authors conducted a systematic review of published cancer
screening studies to identify quality metrics used in navigation programs, as well as to recommend standardized metrics
to define excellence in lung cancer navigation. The authors included 26 studies evaluating navigation metrics in breast,
cervical, colorectal, prostate, and lung cancer. After reviewing the literature, the authors propose the following navigation metrics for lung cancer screening programs: (1) screening rate, (2) compliance with follow-up, (3) time to
treatment initiation, (4) patient satisfaction, (5) quality of life, (6) biopsy complications, and (7) cultural competency.
Keywords: vulnerable populations, patient navigation, navigation metrics, lung cancer, lung cancer screening
Introduction

V

ulnerable populations experience disparities in
health care and health outcomes. Vulnerable populations
are defined as a disadvantaged subset of the community. Although traditionally these subsets have included racial or ethnic minorities, socioeconomically disadvantaged individuals,
uninsured/underinsured persons, children, and the elderly, more
recent literature recognizes previously overlooked groups
such as veterans, immigrants, prisoners, residents of rural
communities, and trans/gender nonconforming persons.1,2

These vulnerable populations experience disparate
health care access and health outcomes because of inequalities in social determinants of health.1,2 In terms of
outcomes in cancer care, disparities in time to diagnosis,
curative treatment, and cancer-specific and overall mortality have been noted among black, Hispanic, and Asian
patients with nearly every tumor type.3 Despite some racial
groups being at high risk, it is important to note that
not every individual in a racial minority is vulnerable.
Social disadvantage is determined by whether the group
as a whole is less advantaged than whites.4 For example,
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indices of low socioeconomic status and low health literacy
have been associated with increased cancer incidence and
cancer mortality.5,6
Ongoing efforts to reduce cancer disparities in vulnerable populations include both large-scale changes in health
care policy, as well as changes at the individual hospital system level as exemplified by the transitioning to a
patient-centered service delivery model through the use of
patient navigation. This review will focus on identifying
metrics that measure the impact of patient navigation on
improving care, specifically for patients at risk for or who
are diagnosed with lung cancer.
Patient navigators have been proposed as a mechanism
to maximize compliance with complex screening programs
for cancer. Although navigation has been discussed in the
literature frequently, there is a lack of consistency regarding the definition and role of navigators. MerriamWebster’s dictionary defines navigation as ‘‘mak[ing]
one’s way through.’’7 Navigation aims to guide patients
through the cancer care continuum to survivorship with
preserved health. One literature review states that a navigator is ‘‘someone who helps assist patients overcome
barriers to care.’’8,9 A navigator’s goal is to help cancer
patients prevail over hurdles to early and effective diagnosis and treatment.9,10
In order to guide patients through early cancer detection
and the cancer care continuum, patient navigation consists
of 3 main phases: (1) navigation to screening, (2) navigation
to diagnostic evaluation, and (3) navigation to treatment.
Patient navigators should provide culturally competent care
and aim to boost patient satisfaction throughout all 3 phases
of navigation (Figure 1 illustrates the process steps).
Patient navigation in cancer was championed initially
at Harlem Hospital in 1990 by Harold P. Freeman, MD, a
prominent New York-based oncologist, in response to disproportionately high breast cancer incidence and mortality
rates in the black community. The program provided lowincome and underinsured women with breast cancer
screening. Navigators took on the role of advocates for patients with abnormal screenings. Navigated patients successfully had a biopsy within a shorter period of time and
more often than non-navigated patients.11 Moreover, the
program increased the rate of early-stage cancer detection
and increased 5-year survival by 31%.12 Early detection of
cancer does not reduce mortality rates alone; it must be
followed by timely treatment.13 Freeman attributed the reduced mortality in part to the process of navigation, which
facilitated prompt diagnosis and treatment, as well as culturally appropriate community outreach and education.
Freeman concluded the success of the program was primarily
because of free and low-cost breast cancer screening and
early diagnosis.13,14
Patient Navigation in Cancer Screening, Diagnosis,
and Management

The National Cancer Institute implemented the Patient
Navigation Research Program (PNRP)15 to address the need
for standardization of navigation programs across health
systems. Initiated in the era before publication of the National Lung Screening Trial (NLST),16 the PNRP focused on
eliminating disparities for screening, follow-up, and treat-
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ment in breast, cervical, prostate, and colorectal cancer in
vulnerable populations at 9 project sites across the United
States. The PNRP found navigation increased diagnostic
resolution after an abnormal screening, decreased time to
diagnostic resolution, and improved treatment initiation in
patients who characteristically do not seek treatment within
90 days of diagnosis. Furthermore, navigated patients reported an increase in satisfaction and quality of life.15 Navigation programs have been shown to increase rates of
cancer screening by 10.8%–17.1% and to increase adherence to follow-up by 21%–29.2%, according to a literature
review.17 Patient navigation programs have been successful
in the screening, diagnosis, and management of breast, colorectal, prostate, and cervical cancer in vulnerable populations.11–13,15
The Case for Patient Navigation in Lung Cancer
Screening, Diagnosis, and Management

An estimated 154,050 Americans will die from lung
cancer in 2018, making it the most preventable and leading
cause of cancer mortality in the United States.18,19 Most
lung cancer patients are diagnosed at an advanced stage and
have a 5-year survival rate of less than 30%.20 Early diagnosis is crucial, as 5-year survival increases to 56% if lung
cancer is found at a localized stage. However, currently,
only 16% of lung cancer cases are diagnosed at an early
stage.19 Smoking accounts for 80% of lung cancer deaths in
the United States, with the quantity and duration of smoking
correlating closely with mortality risk.19 The relative risk for
developing lung cancer in smokers is 25.19
In 2011, the landmark NLST investigated whether lowdose computed tomography (LDCT) or single-view posteranterior chest radiography is more effective in reducing lung
cancer mortality. NLST reported a 20% relative decrease in
lung cancer mortality with annual LDCT compared with
radiography.16 In 2013, the United States Preventive Services Task Force recommended annual lung cancer
screening using LDCT for persons ages 55 to 80 years who
are in good health, have a 30 pack-year or more smoking
history, and currently smoke or have quit within the past 15
years.18 Subsequently, the Centers for Medicare & Medicaid Services approved lung cancer screening as an additional preventive service benefit.18 Despite these and other
recommendations issued by several professional organizations, uptake remains low.18,19 The 2010 National Health
Interview Survey found that only 2%-4% of high-risk
smokers received LDCT. In 2015, 6.8 million smokers were
eligible for LDCT but only 3.9% (262,700) underwent the
procedure.18
When a new screening test becomes available, racial and
socioeconomic disparities emerge in test use, stage at diagnosis, and mortality. Over time these disparities tend to
decline but endure.21,22 LDCT, as a relatively new screening
test, is no exception to this pattern. Blacks are more likely to
have advanced disease, experience less definitive surgery,
and have lower rates of lung cancer survival than whites.
Black patients also are more likely to be unaware of
screening, underinsured, and to have lower socioeconomic
status – factors that contribute to decreased screening rates
for lung cancer.22 Ironically, recent data suggest that
screening with LDCT reduces mortality in black patients

FIG. 1.

A flowchart illustrating the 3 phases of the navigation process. LDCT, low-dose computed tomography.
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more so than in white patients.22 LDCT uptake is essential
in blacks, but also is important across the spectrum of patients at risk for disparities in lung cancer screening. Applying the lessons of Freeman, it is reasonable to believe
that the use of patient navigation in lung cancer screening
and management has the potential to improve outcomes and
reduce lung cancer mortality in blacks and other vulnerable
populations.
Given the probable impact of patient navigation related to
lung cancer screening and follow-up care, it is important to
identify quality metrics that will maximize the benefit of
these important initiatives. Despite the existing literature
on patient navigation, there is a dearth of published data on
navigation in lung cancer and no consistent metrics to
measure the success of navigation in lung cancer care. In
this paper the study team aims to: (1) conduct a systematic
review of existing trials addressing the utilization of patient
navigators for cancer care, (2) extrapolate and define quality
metrics for patient navigation programs, and (3) propose a
set of national metrics to define quality in patient navigation for lung cancer screening, with the ultimate goal of reducing morbidity and mortality from lung cancer in vulnerable
populations.
Methods

The study team performed an independent search of the
PubMed database in order to identify metrics used to assess
the effectiveness of navigation. Using criteria for randomized controlled trials (RCTs), investigators searched for
articles containing ‘‘nurse navigator’’ and ‘‘cancer,’’ ‘‘nurse
navigation’’ and ‘‘cancer,’’ ‘‘oncology nurse navigator,’’
‘‘patient navigation’’ and ‘‘cancer,’’ and ‘‘navigation’’ and
‘‘cancer’’ in May 2018. In order to better focus on lung
cancer, search criteria were widened to any study design that
investigated the impact of patient navigation on lung cancer.
Search terms included ‘‘nurse navigator’’ and ‘‘lung cancer,’’
‘‘nurse navigation’’ and ‘‘lung cancer,’’ ‘‘lung cancer
screening nurse navigator,’’ ‘‘patient navigation’’ and ‘‘lung
cancer,’’ and ‘‘navigation’’ and ‘‘lung cancer.’’ Inclusion
criteria were peer-reviewed RCTs published in the last 15
years. Studies had to address the effectiveness of navigation
in breast, colorectal, cervical, prostate, and lung cancer
compared to usual care. Additionally, retrospective chart reviews on lung cancer navigation that were published in the
last 15 years were considered. Other forms of navigation and
other chronic diseases were excluded. Articles that did not
address important outcome measures were excluded, such as
protocols and studies that did not focus solely on navigation.
Titles and abstracts were screened by 2 investigators (CSS,
JAB). Articles that met the criteria were reviewed and
summarized. Reference lists of included articles were reviewed for pertinent publications. Discrepancies were
mitigated by discussion and consensus. Studies that met the
inclusion criteria underwent a data extraction process that
included author, year, study design, participants, recruitment strategy, intervention, and results. Extracted information was entered and stored in tables available to all
investigators. Data extraction was completed by a single
investigator (CSS) and audited by 2 additional investigators for accuracy (GCK, JAB). Investigators synthesized
findings employing a narrative approach. Because of het-
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erogeneity in the existing literature, results of this review
were summarized descriptively.
Results
Characteristics of reviewed articles

The initial search yielded 368 papers published since
2005; of these 22 unique articles met all inclusion criteria.
Upon concentrating search terms to focus exclusively on
lung cancer navigation, an additional 413 abstracts were
identified. Following review, an additional 4 were obtained
for a total of 26 papers for analysis (Figure 2). The bulk of
studies occurred in the United States, 1 took place in Denmark,23 and 2 in Canada.24,25 The smallest sample size was
21 participants26 and the largest was 5240 participants.24
The majority of studies focused on black, Latino, or broadly
vulnerable populations. Only 1 study targeted Asian and
Pacific Islander populations.27 The 23 RCTs and 3 retrospective chart reviews varied in methodological quality. The
26 trials included in this review are summarized in Table 1;
the 4 studies focusing solely on lung cancer are outlined in
Table 2.
Patient navigation metrics in cancer screening,
diagnosis, and management

Five consistent metrics were found to be related to screening outcomes that are measured in cancer patient navigation
studies. The metrics are: (1) screening rate, (2) compliance
with follow-up, (3) time to treatment initiation, (4) patient
satisfaction, and (5) quality of life. One study discussed cultural
competency. No studies reported complication rates associated
with completing diagnostic studies or results of screening
findings and evaluation.
Screening rate. Screening rate is a fundamental metric
of patient navigation. Navigation programs in vulnerable
populations aim to improve screening uptake. Eight RCTs
measured screening rate, 7 of which concentrated on vulnerable populations. In trials encompassing the general
cancer patient population, navigated patients had higher
uptake in colorectal and lung cancer screenings when
compared to usual care patients.24,28 Low-income and minority patients experienced a substantial increase in cervical,
breast, and colorectal screening when navigated.27,29–33 In
fact, one RCT found vulnerable patients have 1.5 times
greater odds of completing a colonoscopy if they have a
patient navigator.30 Another trial offered culturally-tailored,
language-concordant navigation and found that navigated
patients were more than twice as likely to be screened for
colon cancer when compared to usual care patients.29
Compliance with follow-up. Compliance with follow-up
is a key metric of patient navigation and encompasses
follow-up after suspicious findings as well as continuing
annual screenings. In the studies examined in this review, 7
measured compliance with screening. One RCT on colonoscopy completion after a positive sigmoidoscopy or fecal
occult blood test found navigated patients had higher rates
of completed colonoscopy than usual care patients, though
differences were not statistically significant.34 Trials focusing on vulnerable populations also found navigation to
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FIG. 2.

A flowchart of the literature search and study selection. RCT, randomized controlled trial.

Table 1. Summary of Included Patient Navigation Studies
N=

Multicenter?

Personal Navigation Increases
Colorectal Cancer Screening
Uptake24 (a)
Effect of Patient Navigation on
Breast Cancer Screening
Among African American
Medicare Beneficiaries: A
Randomized Controlled
Trial38 (a)

5240

No

1905

Yes

Breast, Cervical, Patient Navigation for Compreand Colon
hensive Cancer Screening in
High-Risk Patients Using a
Population-Based Health Information Technology System: A Randomized Clinical
Trial31 (a)

1612

Yes

Colon

A Culturally Tailored Navigator 1223
Program for Colorectal Cancer
Screening in a Community
Health Center: A Randomized
Controlled Trial29 (a)

No

Screening rate  More likely to get
and compliany colon cancer
ance with
screening
 More likely to get
follow-up
colonoscopy after
recommendation

Lung

Patient Navigation for Lung
1200
Cancer Screening among Current Smokers in Community
Health Centers: A Randomized Controlled Trial28 (a)
Patient Navigation and Time to 1039
Diagnostic Resolution: Results
for a Cluster Randomized
Trial Evaluating the Efficacy
of Patient Navigation among
Patients with Breast Cancer
Screening Abnormalities,
Tampa, FL44 (a)
933
Patient Navigation Improves
Cancer Diagnostic Resolution:
An Individually Randomized
Clinical Trial in an Underserved Population40 (a)

Yes

Screening rate  Higher uptake of
screening

Yes

Time to treat-  No differences in
ment initiatime to diagnostic
tion
resolution between
0–3 months after an
abnormal mammogram
 Quicker resolution
after 4.7 months
Time to treat-  Quicker time to diment initiaagnostic resolution
tion
after abnormal
screening in all cancers
 Quicker time to diagnostic resolution
after an abnormal
breast, colorectal,
and prostate cancer
screening

Type of cancer
Colon
Breast

Breast

Breast, Colon,
and Prostate

Title (design)

Breast, Cervical, The Ohio Patient Navigation
and Colon
Research Program: Does the
American Cancer Society Patient Navigation Model Improve Time to Resolution in
Patients with Abnormal
Screening Tests?43 (a)
Colon
Patient Navigation for Colonoscopy Completion: Results of
an RCT30 (a)

Yes

862

Yes

843

No

Metrics

Navigated patients’
outcome

Screening rate  Higher colorectal
screening uptake
 Higher screening
Compliance
with followadherence
 Patients who were
up
noncompliant at
baseline had significantly higher adherence to screening
(73.4% vs 45.6%)
Screening rate  Higher screening
rate in all cancers
 Higher screening
rate in breast, cervical, and colorectal
cancer

Significance
of outcomes
 (Odds ratio, 2.11;

confidence interval,
1.87–2.39)
 P < 0.001

Screening rate:
 all cancers
(P < 0.001)
 breast cancer
(P = 0.009)
 cervical cancer
(P = 0.007)
 colorectal cancer
(P < 0.001)
 Screening Rate
(P < 0.001)
 Compliance with
follow-up
(P < 0.001)
 More polyps identified (P = 0.04)
 P < 0.001

 Time to diagnostic

resolution after 4.7
months (P < 0.05)

Time to treatment initiation:
 All cancers
(P < 0.001)
 Breast cancer: BIRADS 3 (P = 0.0003),
BIRADS 0
(P = 0.09)
 Colorectal cancer
(P = 0.0017)
 Prostate cancer
(0.06)
 P = 0.012

Time to treat-  Quicker time to diment initiaagnostic resolution
tion
after abnormal
screening
 Diagnostic resolution was 65% higher
at 15 months
Screening rate  Higher rate of colo-  Screening rate
noscopy completion
(P = 0.021)
 Odds of completing
a colonoscopy was
1.5 times higher
(P = 0.007)

(continued)
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Table 1. (Continued)
Type of cancer
Colon

Title (design)

N=

Multicenter?

Increasing Colon Cancer Screening in Primary Care Among
African Americans37 (a)

764

Yes

Colorectal Cancer Screening
among Ethnically Diverse,
Low-income Patients: A Randomized Controlled Trial33 (a)
Breast, Cervical, Reducing Cancer Screening DisColon, and
parities in Medicare BeneficiProstate
aries Through Cancer Patient
Navigation27 (a)

465

Yes

488

No

Colon

Increasing Colonoscopy Screening for Latino Americans
Through a Patient Navigation
Model: A Randomized Clinical Trial32 (a)

392

No

Breast Cancer, Randomized Controlled Trial of
Colon Cancer
Patient Navigation for Newly
Diagnosed Cancer Patients:
Effects on Quality of Life48 (a)

319

Yes

Colon Cancer

Patient Navigation to Increase
Colorectal Cancer Screening
among Latino Medicare Enrollees: A Randomized Controlled Trial36 (a)
Nurse Navigators in Early Cancer Care: A Randomized,
Controlled Trial45 (a)

303

No

251

Yes

Do Depressed Newly Diagnosed
Cancer Patients Differentially
Benefit from Nurse Navigation?46 (a)
Patient Navigation and Case
Management Following an
Abnormal Mammogram: A
Randomized Clinical Trial35

251

Yes

204

No

Breast and Lung Impact of a Pivot Nurse in
Oncology on Patients with
Lung or Breast Cancer:
Symptom Distress, Fatigue,
Quality of Life, and use of
Healthcare Resources47 (a)
Colon
Results of Nurse Navigator
Follow-up after Positive Colorectal Cancer Screening Test:
A Randomized Trial34 (a)

190

Yes

147

Yes

Colon

Lung, Breast,
and Colon

Lung, Breast,
and Colon
Breast

(a)

Metrics

Navigated patients’
outcome

Significance
of outcomes

 Higher adherence to  Compliance at 6
Compliance
with followscreening at 6
months (P = 0.001)
 Compliance at 12
up
months and 12
months (P = 0.001)
months
Screening rate  Higher rates of co-  P < 0.001
lorectal cancer
screenings

Screening rate  Higher breast, cervi-  Breast cancer
cal, colorectal, and
(P = 0.003)
 Cervical cancer
prostate cancer
(P = 0.001)
screening rates
 Colorectal cancer
(P < 0.001)
 Prostate cancer
(P = 0.008)
 Screening rate: Not
Screening rate  Patients were assigned to regular
significant
 Navigation in Spannavigation or
ish was more effecculturally-tailored
tive in increasing
navigation. There
screening
were no differences
(P = 0.001)
in screening rate
between the types of
navigation.
 30% increase in
screening rate compared to the national
rate
 Patients who were
navigated in only
Spanish were more
likely to be screened
 Quality of life: Not
Quality of life  No differences in
quality of life
significant
 Slightly higher
 Emotional wellscores for emotional
being (P = 0.05)
well-being
 More likely to be
 P = 0.04
Compliance
with followadherent to colorecup
tal cancer screening
 Quality of life: Not
Quality of life  No differences in
and patient
quality of life
significant
satisfaction  Higher patient sat-  Patient satisfaction
isfaction and fewer
(P < 0.05)
problems with care
Quality of life  No difference in de-  Not significant
(depression)
pression scores

 Increased adherence  Compliance with
Compliance
with followto diagnostic resolufollow-up
up and time
tion
(P < 0.001)
to treatment  More timely adher-  Timely adherence
ence
(P = 0.001)
initiation
 Not significant
Quality of life  No difference in
(distress)
quality of life, distress, fatigue level,
or health care usage

 More likely to com-  Not significant
Compliance
with followplete the follow-up
up
colonoscopy after
positive fecal occult
blood test or sigmoidoscopy

(continued)
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Table 1. (Continued)
Type of cancer
Breast

Breast

Colon

Title (design)

N=

The Effect of Patient Navigation
on Time to Diagnosis, Anxiety, and Satisfaction in Urban
Minority Women with Abnormal Mammograms: A Randomized Controlled Trial39 (a)

105

The Effects of Individually Tailored Nurse Navigation for
Patients with Newly Diagnosed Breast Cancer: A Randomized Pilot Study23 (a)

50

A Randomized Controlled Trial
Using Patient Navigation to
Increase Colonoscopy Screening among Low-income
Minorities26 (a)

21

Multicenter?
No

No

No

Navigated patients’
outcome

Metrics
Time to treatment initiation, quality
of life (anxiety), and
patient satisfaction
Quality of life
(anxiety,
distress, and
depression)
and patient
satisfaction

 Time to diagnostic







Compliance
with followup and patient satisfaction




Lung

Lung

Lung

Impact of Nurse Navigation on
Timeliness of Diagnostic
Medical Services in Patients
with Newly Diagnosed Lung
Cancer41 (b)
Implementation of a Lung Cancer Nurse Navigator Enhances
Patient Care and Delivery of
Systemic Therapy at the British Columbia Cancer Agency,
Vancouver25 (b)

The Effect of a Lung Cancer
Care Coordination Program on
Timelines of Care42 (b)

resolution (25 vs
42.7 days)
Lower anxiety
scores
Higher patient satisfaction
No difference in
quality of life
Less anxiety, distress, and depression
at 12 months
Higher satisfaction
with treatment and
rehabilitation
Compliant with recommendation to get
colon cancer
screening (54% vs
13%)
86% had excellent or
very good colon
prep
100% satisfied with
navigation
Suspicion of cancer
to treatment (45 vs
64 days)

460

No

Time to treat- 
ment initiation

408

No

Time to treat-  More patients rement initiaceiving therapy
 Undergoing molecution and
lar testing (91% vs
number of
62%)
patients receiving sys-  Referral to oncology
consult (15.5 vs
temic thera18 days)
py
 Referral to systemic
treatment (38 vs
48 days)
 Referral to radiation
(8 vs 10 days)
 Referral to radiotherapy (11.5 vs
18 days)

352

No

(a)

Randomized controlled trial.
Retrospective chart review.

(b)

354

Significance
of outcomes
 Time to treatment

initiation (P = 0.001)

 Anxiety scores

(P < 0.001)

 Patient satisfaction

(P < 0.001)
 Quality of life: Not

significant

 Decrease in anxiety

(P = 0.02), distress
(P < 0.01), and depression (P = 0.04)
 Patient satisfaction
(P < 0.01)
 Not significant

 P < 0.001

 Number of patients

in therapy (P = 0.05)

 Patients undergoing








Time to treat-  25-day reduction
ment initiafrom abnormal find
tion and
ing to treatment
number of  Stage I/II diagnoses
(48% vs 32%)
patients diagnosed
early

molecular testing
(P < 0.001)
Reduction in time
from referral to oncology consult
(P = 0.11)
Reduction in time
from referral to
treatment
(P = 0.016)
Reduction in time
from referral to radiation (P = 0.005)
Reduction in time
from referral to radiotherapy
(P < 0.001)
Time to treatment
initiation (P = 0.015)
Number of patients
diagnosed early
(P = 0.006)
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Table 2. Summary of Included Lung Cancer Patient Navigation Studies
Title

N=

Design

Patient Navigation for 1200 Randomized
Lung Cancer
controlled
Screening among
trial
Current Smokers in
Community Health
Centers: A Randomized Controlled
Trial28
Impact of Nurse Navi- 460 Retrospective
gation on Timelichart review
ness of Diagnostic
Medical Services in
Patients with Newly
Diagnosed Lung
Cancer41
408 Retrospective
Implementation of a
chart review
Lung Cancer Nurse
Navigator Enhances
Patient Care and
Delivery of Systemic Therapy at the
British Columbia
Cancer Agency,
Vancouver25

The Effect of a Lung
Cancer Care Coordination Program on
Timelines of Care42

352 Retrospective
chart review

Multicenter?
Yes

Metrics
Screening rate

Navigated patients’ outcome
 Higher uptake of

Significance
of outcomes
 P < 0.001

screening

No

No

Time to treatment
initiation

 Suspicion of cancer to

 P < 0.001

treatment (45 vs
64 days)

Time to treatment ini-  More patients receiving
tiation and number
therapy
of patients receiving  Undergoing molecular
testing (91% vs 62%)
systemic therapy
 Referral to oncology
consult (15.5 vs
18 days)
 Referral to systemic
treatment (38 vs
48 days)
 Referral to radiation (8
vs 10 days)
 Referral to radiotherapy
(11.5 vs 18 days)

 Number of patients in

Time to treatment ini-  25-day reduction from
tiation and number
abnormal finding to
of patients diagtreatment
 Stage I/II diagnoses
nosed early
(48% vs 32%)



be effective in increasing compliance with screening programs and compliance through to diagnostic resolution in
breast and colorectal cancer.26,29,35–38 One RCT on colonoscopy adherence among low-income minorities found that
54% of patients successfully completed colonoscopy compared to 13% of usual care patients. Additionally, 86% of
navigated patients had excellent or very good colonoscopy
prep. There was not a statistically significant difference
between navigated and usual care patients, but compliance
with screening preparation is worth noting.26 One study that
utilized culturally-trained patient navigators was successful
in increasing compliance with annual and follow-up
screenings.29 No studies evaluated the impact of navigation
on compliance with follow-up in lung cancer patients.
Time to treatment initiation. Time to treatment initiation
is the umbrella metric for diagnostic and treatment timelines.
Time to treatment initiation includes time from suspicious
finding to active observation, chemotherapy, radiation, biopsy, or surgical intervention. Five RCTs measured time to
treatment initiation, 4 of which focused on vulnerable populations. In vulnerable populations patient navigators shortened time to diagnosis and increased timely adherence with
diagnostic evaluation in breast, colorectal, and prostate can-

therapy (P = 0.05)

 Patients undergoing







molecular testing
(P < 0.001)
Reduction in time from
referral to oncology
consult (P = 0.11)
Reduction in time from
referral to treatment
(P = 0.016)
Reduction in time from
referral to radiation
(P = 0.005)
Reduction in time from
referral to radiotherapy
(P < 0.001)
Time to treatment initiation (P = 0.015)
Number of patients diagnosed early
(P = 0.006)

cer.35,39,40 A retrospective chart review evaluating the impact
of patient navigation on time to treatment initiation in lung
cancer patients found a significant decline in time from referral to primary consult, treatment, and radiation.25 In
comparison to usual care patients, navigated patients with
lung cancer experienced an average reduction of 22 days
from abnormal finding to treatment.41,42 Navigated patients
with abnormal breast, cervical, or colorectal screenings experienced significantly quicker times to diagnostic resolution
at 6 months compared to usual care patients. The diagnostic
resolution rate at 15 months was 65% higher in navigated
patients.43 The impact of navigation on time to diagnostic
resolution in vulnerable populations may not be seen immediately; however, the impact is apparent and sustained
over longer periods of follow-up.44
Patient satisfaction. Patient satisfaction is a patientreported metric and can be applied to satisfaction with
navigation or with the entirety of care. Four reviewed RCTs
measured patient satisfaction. Breast, colon, and lung cancer
patients who had patient navigation reported significantly
higher levels of satisfaction than usual care patients.23,45
Among vulnerable populations, one RCT found navigated
women with abnormal mammogram findings reported
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Table 3. Summary of Proposed Lung Cancer Patient Navigation Quality Metrics

Metric

Metric includes

Screening rate

Number of participants getting
screened
Compliance with Annual screenings and adherfollow-up
ence to follow-up screenings
Time to treatment Time from suspicious finding to
initiation
diagnostic resolution, active
observation, chemotherapy,
radiation, biopsy, and surgical
intervention
Patient
Satisfaction with navigation and
satisfaction
satisfaction with overall care

Number of studies
that measured the
metric (statistically
significant benefit)
824,27–33
(724,27–31,33)
726,29,34–38
(529,35–38)
825,35,39–44
(825,35,39–44)

423,26,39,45
(323,39,45)

Quality of life

Quality of life as a whole as well
as levels of depression, distress, and anxiety

623,39,45–48
(223,39)

Biopsy
complications
Cultural
Competency

Number of biopsy complications

0

a

Language concordance, shared
decision making, patient perception of respect and discrimination, as well as health
literacy

1a

29

How to measure the
metric

Type of metric
measurement

Medical records or
insurance claims49
Medical records or
insurance claims49
Medical records or
insurance claims49

Quantitative, ‘‘hard’’
measure
Quantitative, ‘‘hard’’
measure
Quantitative, ‘‘hard’’
measure

Patient Satisfaction
with Cancer-Related
Care Survey49,53 or
Satisfaction with Patient NavigationInterpersonal
Scale49,54
Functional Assessment
of Cancer Therapy
Survey,49,55 the
Patient-Reported
Outcomes Measurement Information
System,49,56 the Hospital Anxiety and
Depression
Scale,23,57, or the
Zung Self Rating
Anxiety Scale39,58
Medical records or
insurance claims
Perceived Similarity to
Patient Navigator
Scale49,59

Patient reported,
‘‘soft measure’’

Patient-reported,
‘‘soft’’ measure

Quantitative, ‘‘hard’’
measure
Patient reported,
‘‘soft’’ measure

Study including cultural competency evaluated the impact on screening rate and compliance with follow-up.

significantly higher patient satisfaction than usual care patients.39 Another RCT evaluating the effectiveness of patient
navigation assisting vulnerable populations overcome barriers to colorectal screening found that 100% of navigated
patients were satisfied with navigation services.26
Quality of life. Quality of life encompasses levels of
anxiety, depression, and distress. Six RCTS measured
quality of life. An RCT that involved recently diagnosed
breast cancer patients found navigated patients had lower
levels of distress, anxiety, and depression after 12 months.23
In contrast, another trial found no difference in depression
scores between navigated and non-navigated patients.46
Four RCTs found navigated patients and usual care patients
had no significant differences in quality of life.23,45,47,48
Conversely, vulnerable women with abnormal mammogram
results reported lower levels of anxiety in the navigation
group than in the usual care group.39

Discussion and Identifying Key Quality Metrics
for Patient Navigation in Lung Cancer Screening

Patient navigation has been successfully implemented as
a way to reduce cancer disparities in vulnerable populations.
Thus far, navigation programs in breast, colon, cervical, and
prostate cancer have been effective in eliminating some
barriers vulnerable populations face when seeking cancer
care.15 In lung cancer, no studies investigated navigation’s
impact on compliance with follow-up and no studies focusing solely on lung cancer measured patient satisfaction or
quality of life.
Because of the recent introduction of LDCT, history
suggests disparities in lung cancer screening and mortality
will rise, especially among vulnerable populations.21,22 In
order to address this, the study team proposes utilizing patient navigation programs with the implementation of key
quality metrics that would allow full benefits for both patients and health care systems.

LUNG CANCER NAVIGATION IN VULNERABLE POPULATIONS

Based on this review of the literature, the team proposes
the following metrics for lung cancer navigation programs –
(1) screening rate, (2) compliance with follow-up, (3) time to
treatment initiation, (4) patient satisfaction, and (5) quality of
life – as well as adds 2 additional metrics: (6) biopsy complications and (7) cultural competency (Table 3).
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Care survey to look at satisfaction with care.49,53 To address
satisfaction with navigation, programs can use the Satisfaction with Patient Navigation-Interpersonal scale.49,54
Navigation increases levels of patient satisfaction in vulnerable patients.26,39
Quality of life

Screening rate

Screening rate is a core metric for vulnerable population
navigation programs in lung cancer and can be measured
objectively with medical records or through insurance
claims data.49 Increasing lung cancer screening rates in
vulnerable populations through navigation may decrease
disparities and lung cancer mortality.28 LDCT is a newer
screening test; thus, uptake is currently low. Fewer than 4%
of eligible Americans get screened annually. Vulnerable
populations are even less likely to be aware of the test.22
Considering this lack of knowledge and the benefits of early
detection, screening rates need to be increased.19,22 Navigation programs have success with increasing general cancer detection rates and lung cancer screening uptake.28 In
vulnerable populations, patient navigation successfully increases the rate of cancer screenings.29–32
Compliance with follow-up

Patient navigation programs in lung cancer that are tailored for vulnerable populations should measure compliance with follow-up as a metric. Compliance can be
measured quantitatively using medical records or insurance
claims.49 LDCT requires annual screening and follow-up,
which highlights the need for navigation. Vulnerable
populations, particularly blacks, may be more likely to be
lost to follow-up. In fact, one study found that of 15 black
patients with Lung-RADS 3 who required further imaging,
6 patients did not present for follow-up.50 Patient navigation improves compliance with screening programs and
compliance through to diagnostic resolution in vulnerable
populations.26,29,35,36
Time to treatment initiation

The metric time to treatment initiation should be measured in lung cancer navigation programs in order to maximize favorable outcomes and minimize cancer morbidity
and mortality. Vulnerable patients experience treatment
delays more than the general population.3,51 Because lung
cancer mortality is closely related to stage of presentation, it
is imperative to get patients into treatment promptly after
suspicious findings.19 Time to treatment initiation can be
measured with medical records or insurance claims.49 Patient navigation for vulnerable populations shortens time to
diagnosis.39,40
Patient satisfaction

Medicare already emphasizes the importance of patient
satisfaction through the Consumer Assessment of Healthcare Providers and Systems and Hospital Consumer Assessment of Healthcare Providers and Systems.52 Therefore,
patient satisfaction is a key metric for lung cancer navigation. Patient satisfaction can be measured as a self-reported
metric with the Patient Satisfaction with Cancer-Related

Quality of life is a patient-based self-reported metric for
lung cancer navigation. This metric contains anxiety, depression, distress, and overall quality of life. Quality of life can be
measured using the validated Functional Assessment of Cancer Therapy survey.49,55 Anxiety, depression, and distress can
be measured using surveys from the Patient-Reported Outcomes Measurement Information System,49,56 the Hospital
Anxiety and Depression Scale,23,57 or the Zung Self Rating
Anxiety Scale.39,58 Navigated patients do not report a difference in quality of life23,47 or depression.46 However, navigation reduces anxiety in vulnerable populations.39
Biopsy complications

Biopsy complications should be a metric for lung cancer
navigation programs despite a lack of existing literature.
Patient navigators are tasked with tracking patients over
time to ensure completion of screening and treatment. Navigators also help coordinate follow-up, including timely
follow-up of any complications.17 The study team proposes
that because patient navigators successfully improve rates
of screening and compliance in vulnerable populations,
they would help reduce biopsy complications by facilitating appropriate follow-up at all stages. The NLST found
the rate of at least 1 complication from a diagnostic evaluation procedure after an abnormal screening test was
lower in LDCT patients than in radiography patients.16
Navigators may be able to reduce biopsy complications in
vulnerable populations with timely follow-up, and perhaps
reduce morbidity and mortality. The team recommends that
biopsy complications be measured with medical records or
insurance claims.49 Future research is needed to investigate
a patient navigator’s impact on biopsy outcomes in lung
cancer.
Cultural competency

Cultural competency is a vital metric for patient navigation in lung cancer. Cultural competency can be a patientreported measure, recorded with the Perceived Similarity to
Navigator Scale, which is adapted from the Perceived Similarity to Physician Scale.49,59 Cultural competence encompasses language, shared decision making, respect, and
discrimination.49 These are important concepts for connecting with vulnerable populations. Black patients report
an increase of medical mistrust and discrimination that
prevents them from seeking care and contributes to advanced cancer stage presentation, and thus mortality disparities.51 The PNRP found language interpretation is one of
the main barriers to seeking cancer care in patients with
abnormal screenings.15 Shared decision making is a concept
discussed by the National Cancer Society and should be part
of annual lung cancer screening.19 Culturally-trained navigators would also be able to assist vulnerable patients with
increasing their health literacy and thus decrease disparities
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in care.5 Freeman, the creator of patient navigation, felt
navigation was successful in part because of culturally appropriate education and outreach.13 When cultural competency is encompassed in navigation programs, screening
rates and compliance increase among vulnerable populations.29 However, no studies were identified that measured
the cultural competency of navigators. Future studies should
evaluate what is meant by cultural competency and the efficacy of culturally-competent patient navigators working
with vulnerable populations in lung cancer programs.
Cost-effectiveness. Although cost-effectiveness is not a
patient navigation metric included in this review, it is worth
noting the importance of evaluating patient and system costs
of patient navigation programs. Patient navigation programs
must meet the standards of excellence set forth by the
proposed metrics and should be cost-effective in order to
justify centralized implementation in health systems and in
other settings. Compared to usual care, patient navigation
programs have been found to be cost-effective in cancer
screening and along the continuum of care.60,61 A cervical
cancer screening patient navigation program tailored to
vulnerable populations found navigation to be cost-effective
compared to usual care.62 A capitated payment lung cancer
treatment patient navigation program for Medicare patients
was cost-effective with an incremental cost-effectiveness
ratio of $19,312 per quality-adjusted life year.63 A patient
navigation program at Henrico Doctors’ Hospital found a
navigation model assigning breast cancer patients to a
navigator at time of suspicious finding through 12-months
post diagnosis was effective in increasing revenue, standardizing care, and increasing patient retention throughout
the care continuum. An unintended consequence was an
increase in revenue, so that after 1 year, the program covered the costs of patient navigation.64 Further research is
needed to investigate both short-term and long-term costeffectiveness of patient navigation programs in lung cancer
screening aimed at vulnerable populations.
Phases of navigation. Patient navigation in cancer
screening involves 3 main phases: (1) navigation to screening, (2) navigation to diagnostic evaluation, and (3) navigation to treatment. Navigation to screening consists of
navigators reaching out to patients, identifying those who
satisfy eligibility criteria, and offering navigation services,
which may include education, shared decision making, and
appointment scheduling for lung cancer screening. Navigation success is measured by the screening rate metric. The
second phase, navigation to diagnostic evaluation, involves
helping patients complete follow-up assessments after an
abnormal screening test and facilitating annual screening.
Among persons with suspicious findings, navigators would
monitor follow-up after an abnormal LDCT result and help
to resolve any complications that might result from diagnostic evaluation. Navigation to diagnostic evaluation is
measured using the metric compliance with follow-up. The
final stage of the navigation process, navigation to treatment, involves ensuring that diagnosed patients receive
prompt treatment and helping patients receive care that can
maximize the likelihood of recovery and quality of life.
Specifically, in lung cancer, this would include following
patients with a malignancy and ensuring they receive

SHUSTED ET AL.

treatment quickly as well as providing advice, compassion,
and further information about treatment options in an effort
to reduce anxiety, distress, and depression. The metrics
time to treatment initiation, quality of life, and biopsy
complications measure navigation to diagnostic evaluation.
Navigation to diagnostic evaluation also can measure
survival rates of navigation programs and this metric
should be followed, though meaningful results may take 2–
5 years post treatment in order to have the greatest clarity
of impact. Cultural competency and patient satisfaction
metrics should be measured throughout the navigation
process.
Navigation programs have been shown to increase
screening rates, raise compliance with follow-up, shorten
time to treatment initiation, and improve quality of life and
patient satisfaction.28,38,39,41,45 These factors, paired with a
hypothesized reduction in biopsy complications, and culturally competent care focused on vulnerable patients who
may distrust health care systems, lack health literacy, need
interpretation services, and others who may fall through
safety net programs, are hallmarks of patient navigation in
lung cancer. Patient navigation programs that contain these
key features will improve patient outcomes as well as increase patient retention in the health care system. An increase in patient retention can lead to an increase in net
revenues as well as in downstream revenues, allowing patient navigation programs to be a cost-effective option for
hospitals and payers.64 In the final analysis, improvements
in patient outcome should be the ultimate goal, but savings
also might come from preventing late-stage cancers from
developing.
In order to create a successful lung cancer screening patient navigation program aimed at vulnerable populations,
an institution should be organized to meet the proposed
quality metrics in a cost-effective manner. Patient navigation programs should aim to increase screening rates and
compliance with follow-up, decrease time to treatment initiation and biopsy complications, improve quality of life,
and provide culturally competent care that focuses on patient satisfaction and long-term survivorship of patients. If a
navigation program contains these key components, the
study team believes it will be successful in the ultimate goal
of reducing morbidity and mortality from lung cancer in
vulnerable populations.
Strengths and limitations. The strengths of this study
include the meticulous nature of the literature search and the
rigor of the inclusion criteria. The majority of vulnerable
populations examined in included articles were based on
socioeconomic status and race, leaving gaps in what is
known about navigation in other vulnerable populations
such as veterans, trans/gender nonconforming people, and
residents of rural communities. Moreover, the majority of
studies dealing with race involved blacks and Hispanics,
with only 1 study examining Asians. Although there is
limited representation of many vulnerable populations in the
navigation literature, the study team believes that these
metrics are generalizable and beneficial across the spectrum
of those who are vulnerable to disparities in lung cancer
screening. Further research is needed to fully investigate the
efficacy of patient navigation programs focused on other
facets of vulnerable populations, particularly because the
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definition of vulnerable populations encompasses a large
portion of the population who are at risk for disparate health
outcomes.
A lack of consistency in metrics provided a challenge for
synthesizing trials. Numerous trials investigate dissimilar
cancers and metrics. Heterogeneity in published literature
made conclusive declarations about patient navigation
quality metrics difficult. Despite the lack of quantitative
findings, a qualitative review of trials provides a comprehensive overview of metrics measured in cancer navigation
programs. The present review suggests quality metrics for
future patient navigation programs focused on lung cancer
in vulnerable populations.
Conclusion

This systematic review indicates that patient navigator
programs can improve screening rates, compliance with
follow-up, time to treatment initiation, patient satisfaction,
and quality of life among vulnerable populations. Specifically, in lung cancer, navigated patients have demonstrated
greater screening uptake and more rapid initiation of therapy, although gaps in knowledge related to program implementation and longer term outcomes remain.
Based on this analysis, the study team recommends that
lung cancer screening programs aimed at vulnerable populations utilize patient navigation along with tracking the
following metrics: (1) screening rate, (2) compliance with
follow-up, (3) time to treatment initiation, (4) biopsy complications, (5) patient satisfaction, (6) quality of life, and (7)
cultural competency.
Although this proposal identifies metrics that should be
followed for any patient navigation program, the overall
number of cancers detected, nodule characteristics, incidental findings, and patient outcomes should be followed
and would be expected as part of the current American
College of Radiology (ACR) Reporting and Data Systems
(RADS).65 ACR programs utilizing navigation must track
and report RADS data in order to ensure compliance with
follow-up and prompt treatment initiation in vulnerable
patients. In addition, all navigated patients undergoing
lung cancer screening must receive smoking cessation
counseling in order to comply with the expectations of the
program.
To implement a high-quality navigation program that
succeeds in these areas, the study team proposes that patient
navigators working within lung cancer screening programs
aimed at vulnerable populations have a set of specific skills.
Navigators must have an understanding of cancer biology
and lung pathophysiology; knowledge of symptoms, side
effects, and complications of treatments; the ability to advise both patients and their loved ones; an understanding of
informed consent, patient confidentiality, and the Health
Insurance Portability and Accountability Act; as well as
strong familiarity with shared decision making and cultural
competency. Funding for patient navigation programs across
the United States should be based on the tracking and reporting of these core metrics. If programs are able to meet
these criteria reliably, the program should receive funding
and reimbursement from insurance payers. Future research
should investigate how to negotiate and propose contracts
for reimbursement in lung cancer patient navigation with the
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ultimate goals of enhancing patient-centered care and improving lung cancer mortality.
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